Biosimilars Missing In Action: FDA, Sponsors Quiet About Pending Applications
Executive Summary
Approval of Sandoz's Zarxio aside, dearth of advisory committee meeting announcements and sponsors' reluctance to discuss status of 351(k) filings suggests regulatory road has not been smooth for some early biosimilar candidates.
You may also be interested in...
Pfizer Excludes EU Biosimilar Experience From US Epoetin Application
Even though US product has same cell line and drug product formulation as EU-approved Retacrit, Hospira subsidiary did not bridge to it in its US biosimilar application, meaning US FDA could not consider EU safety and efficacy experience.
Pfizer Excludes EU Biosimilar Experience From US Epoetin Application
Even though US product has same cell line and drug product formulation as EU-approved Retacrit, Hospira subsidiary did not bridge to it in its US biosimilar application, meaning US FDA could not consider EU safety and efficacy experience.
Hospira’s Inflectra, EU’s First Biosimilar mAb, Will Challenge Skeptics
Hospira’s Inflectra becomes the first biosimilar monoclonal antibody to be authorized in Europe – but pricing and overcoming doctors’ skepticism looks like the key to real EU success.